Colorectal Cancer: MEK Inhibitors Promote Resistance

Forty-five percent of colorectal cancers are driven by mutations causing overactivation of the Ras signaling pathway. MEK inhibitors mitigate this overactivation, so why are they ineffective in the treatment of colorectal cancer? Researchers at the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) and the Mannheim University Medical Center have now found a possible explanation: in colorectal cancer, MEK inhibitors activate signaling of the Wnt pathway, thereby causing stem c...
Continue reading

Avelumab/Axitinib Approved: Advanced Renal Cell Carcinoma

​ The FDA has approved avelumab (Bavencio®, EMD Serono, Inc.) in combination with axitinib (Inlyta®, Pfizer Inc.) as first-line treatment for advanced renal cell carcinoma (RCC). Avelumab is an anti–programmed death ligand 1 (anti–PD-L1) antibody, a type of immune checkpoint inhibitor. Axitinib, a vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor (TKI), improves tumor infiltration by immune cells. It has antiangiogenic activity, meaning that it prevents tumors from gr...
Continue reading

Tozuleristide Enables Fluorescence-Guided Surgery in Glioma

​ For patients with gliomas, tumors that begin in the glial cells of the brain and spinal cord, fluorescence-guided surgery (FGS) can improve the extent of surgical resection by enabling neurosurgeons to better see the margins of the malignancies that they are trying to remove. A recent study has revealed that when used with a new, high-sensitivity near-infrared camera, tozuleristide (BLZ-100) provides effective imaging for FGS in adults with newly diagnosed or recurrent gliomas. The high-sensit...
Continue reading

CAR T-Cell Therapies: Survey of Oncology Nurses Reveals Much to Be Learned

​ Chimeric antigen receptor (CAR) T-cell therapy is a form of immunotherapy in which a patient's own T cells are collected and genetically altered to target cancer cells. Although CAR T-cell therapies have shown encouraging results in patients with acute lymphoblastic leukemia and B-cell lymphomas, they are associated with several serious adverse events, including cytokine release syndrome, neurotoxicity, tumor lysis syndrome, and graft-versus-host disease.  In light of the growing use of C...
Continue reading

Multiple Myeloma: bb2121 CAR T-Cell Therapy With James Kochenderfer, MD

Chimeric antigen receptor (CAR) T-cell therapy has shown great promise in hematologic malignancies, with treatments currently FDA approved for aggressive, refractory non-Hodgkin lymphoma and for relapsed/refractory acute lymphoblastic leukemia in patients up to the age of 25. Now, a phase 1 clinical trial of bb2121, a CAR T-cell therapy targeting B-cell maturation antigen (BCMA), has demonstrated antitumor activity in patients with heavily pretreated multiple myeloma. In this interview with i3 H...
Continue reading

© Copyright 2019 i3 Health. All rights reserved.